求翻译:aggressive B-cell lymphoma是什么意思?待解决 悬赏分:1 - 离问题结束还有 aggressive B-cell lymphoma问题补充:匿名 2013-05-23 12:21:38 侵袭性B细胞淋巴瘤 匿名 2013-05-23 12:23:18 侵略性B细胞淋巴瘤 匿名 2013-05-23 12:24:58 进取的B细胞淋巴瘤 匿名 2013-05-23 12:26:38 ...
Bulky aggressive B-cell lymphoma: to radiate or not to radiate--that is the question. Kahl BS. Bulky aggressive B-cell lymphoma: to radiate or not to radiate--that is the question. J Clin Oncol. 2014;32:1097-1098... BS Kahl - 《Journal of Clinical Oncology Official Journal of the Am...
Mantle cell lymphoma (MCL) is a non-Hodgkin's lymphoma of B cell lineage, The blastoid variant ofMCL is characterized by high mitotic rate, and both clinically and histologically more aggressive than com-mon MCL. We used the cDNA array t... Y Zhu,J Hollmen,R Oinonen,... - 《European...
Patients with aggressive B-cell lymphoma have many new options for treatment, including chimeric antigen receptor (CAR) T cell therapies like axicabtagene ciloleucel (Yes Carta) and lisocabtagene maraleucel (Breyanzi), antibody drug conjugates, and cellular therapies. ...
Introduction Chimeric antigen receptor (CAR)-T cell therapy is a promising immunotherapeutic strategy approved for the treatment of relapsed or refractory (r/r) B-cell lymphomas (e.g. diffuse large B cell lymphoma (DLBCL), mantel cell lymphoma (MCL), follicular lymphoma (FL)) after two or mo...
We chose 2 large B-cell lymphoma (LBCL) cell lines (MS, McA) previously established in our lab. Nuclear fractions from these cells were incubated with CD40 antibody and coimmunoprecipitation analyses were performed (Figure 1A). When CD40 was precipitated, c-Rel was also coimmunoprecipitated in...
Researchers at the National Institutes of Health (NIH) have developed a non-chemotherapy treatment regimen that is achieving full remissions for some people with aggressive B-cell lymphoma that has come back or is no longer responding to standard treatme
CD8 marker is not unique to primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma (pc CD8+ AECTCL). Moreover, it occurs in seven other entities presented in the following table. There is a certain clinical and morphological overlap o
PURPOSE: The standard treatment for relapsed diffuse large B-cell lymphoma (DLBCL) is salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantation (ASCT). The impact of maintenance rituximab after ASCT is not known. PATIENTS AND METHODS: In total, 477 patients with ...
Figure 2. Apoptosis of Lymphoma Cells Promotes Tumor Angiogenesis (A) Representative HIF-1α IHC of xenograft tumors, BL2 (left) and BL2-Bcl-2 (right) (n = 5–6). (B and C) Reduced angiogenesis in tumors with suppressed apoptosis is associated with low cell proliferation. Quantification of...